Intratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targets
Esther Coronado(Leitat Technological Center), Jaime Font de Mora(Bellvitge University Hospital), Luis Rubio(Hospital Universitari i Politècnic La Fe), Adela Cañete(Universitat de València), Antonio José Cañada Martínez(Leitat Technological Center), Francisco Vera‐Sempere(Instituto de Investigación Biosanitaria de Granada), Victoria Castel, Yania Yáñez(Hospital Universitari i Politècnic La Fe), Ruth Ladenstein(St Anna Children's Hospital), Enrique Vidal(Leitat Technological Center), Joaquín Panadero
Cited by 9
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
|Journal of Clinical Oncology|1993|2.3k
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|641